Waddell & Reed Financial’s AstraZeneca AZN Stock Holding History

Waddell & Reed Financial’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$46.3M	Buy	466,006 +396,272	+568%	+$39.8M	0.1%	247
2020 Q4	$6.97M	Hold	69,734	–	–	0.01%	425
2020 Q3	$7.64M	Sell	69,734 -131	-0.2%	-$14.6K	0.02%	405
2020 Q2	$7.39M	Sell	69,865 -262,235	-79%	-$27.1M	0.02%	399
2020 Q1	$29.7M	Sell	332,100 -104,285	-24%	-$9.82M	0.1%	232
2019 Q4	$43.5M	Sell	436,385 -43,938	-9%	-$4.14M	0.11%	218
2019 Q3	$42.8M	Buy	+480,323	New	+$41.6M	0.11%	214
2014 Q3	–	Sell	-562,862	Closed	-$41.8M	–	533
2014 Q2	$41.8M	Buy	+562,862	New	+$40.7M	0.06%	261

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Waddell & Reed Financial's AZN Position: Q1 2021 in Review

Waddell & Reed Financial increased its AstraZeneca (AZN) stake by 568% in Q1 2021, buying an estimated $39.8M and bringing the position to 466,006 shares worth $46.3M. The position accounts for 0.1% of the portfolio, ranked #247.

Waddell & Reed Financial first reported a position in AZN in Q2 2014 and has held it in 8 quarters since. 756 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

Waddell & Reed Financial held 466,006 shares of AstraZeneca worth $46.3M as of Q1 2021.
Waddell & Reed Financial bought 396,272 AstraZeneca shares in Q1 2021, an estimated $39.8M.
AstraZeneca made up 0.1% of Waddell & Reed Financial's portfolio in Q1 2021, its #247 holding.
Waddell & Reed Financial first reported a position in AstraZeneca in Q2 2014 and has held it in 8 quarters since.
756 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.